TDK Corporation (TSE 6762) announces an £11.5m investment package to redevelop its TDK-Lambda manufacturing facility in Ilfracombe, UK. The investment, which will be staged over the next three and a half years, will enable the company to increase production capacity by 50%.

The original factory was built over 50 years ago with further expansion in the mid-1980s. While the company has invested heavily in new equipment and building upgrades over these years, including the addition of a £1 million EMC Centre in 2019, it is now time to redevelop the site. The redevelopment will increase manufacturing space, expand the R&D facilities, and radically overhaul and automate the end-to-end material flow.

According to market research company Omdia, the global power supply market is forecast to reach almost $26bn in 2024, driven by the rapidly expanding digitalisation of economies, increasing healthcare demands and renewable energy trends. Also, noting customers’ heightened awareness of the need for trusted, dependable suppliers due to recent events – such as the USA/China tariffs and COVID-19 pandemic – the planned expansion will provide further supply chain robustness within the TDK-Lambda manufacturing network, especially for the European market.

The redevelopment programme will be split up into a four-stage process to ensure continuity of production and services. Stage one will be the construction of new offices, including employees’ facilities and a health and fitness centre, on the North and West faces. Upon completion, the South facing office will be extended to expand the R&D, product verification & test, and manufacturing engineering facilities. The link area between the two factory buildings will then be infilled, and Smart, Lean storage facilities and AGVs for material handling installed. Finally, the manufacturing areas will be reconfigured with designated Front End (PCB assembly) and Back End (configuration & test) production areas.

TDK-Lambda healthcare power supplies are used in critical medical and laboratory applications globally. “Since the COVID-19 outbreak, delivery quantities to certain healthcare and bio-diagnostic customers have increased by six to tenfold,” says Geoff Wilby, Managing Director of TDK-Lambda UK.

Among the UK designed products are the 100W CUS100ME for portable ventilators, the 175W rated NV series for ventilators, the 300W EFE300M for virus detection, the 550W Vega modular power supply for COVID-19 swab testing and the QM5 700W modular power supply for mobile X-ray equipment.

For more information about the full range of TDK-Lambda medical and healthcare power supplies, please call TDK-Lambda UK directly on +44 (0)1271 856600 or visit the TDK-Lambda EMEA website at: www.emea.lambda.tdk.com/medical.